Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 10/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | MPC2 | O95563 | 2/20 | 0.43 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8205210 | 0.93 | MAPT (0.52) | MAPTMEN1KMT2ATDP1CYP3A4 | |
| SCHEMBL13267915 | 0.92 | MEN1 (0.44) | MAPTMEN1KMT2ATDP1CYP3A4 | |
| SCHEMBL10636080 | 0.92 | CYP3A4 (0.48) | MAPTMEN1KMT2ATDP1CYP3A4 | |
| SCHEMBL10636395 | 0.88 | CYP3A4 (0.49) | MAPTMEN1KMT2ATDP1CYP3A4 | |
| SCHEMBL10640616 | 0.88 | CYP3A4 (0.49) | MAPTMEN1KMT2ATDP1CYP3A4 | |
| SCHEMBL13847346 | 0.86 | MAPT (0.48) | MAPTMEN1KMT2ATDP1CYP3A4 | |
| SCHEMBL10641609 | 0.85 | MEN1 (0.47) | MAPTMEN1KMT2ATDP1CYP3A4 | |
| SCHEMBL9311289 | 0.85 | MEN1 (0.55) | MAPTMEN1KMT2ATDP1CYP3A4 | |
| SCHEMBL12521781 | 0.85 | MEN1 (0.54) | MAPTMEN1KMT2ATDP1CYP3A4 | |
| Troglitazone SCHEMBL1536757 | 0.84 | MEN1 (0.64) | MAPTMEN1KMT2ATDP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0075117-B1 | 2H-1,2,4,6-THIATRIAZINE-1,1-DIOXIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES | BASF Aktiengesellschaft (DE) | 1985-03-13 | — | — | EP | claimed |
| JP-61036284-A | — | — | None | — | — | JP | disclosed |
| WO-2011091033-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | BRAINCELLS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| US-20100184806-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | BRAINCELLS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-5104888-A | Anticholesterol or antidiabetic agents | SANKYO COMPANY, LIMITED (JP) | 1992-04-14 | — | — | US | disclosed |
| EP-0207581-B1 | THIAZOLIDINE DERIVATIVES, THEIR PREPARATION AND USE | SANKYO COMPANY LIMITED (JP) | 1990-09-12 | — | — | EP | disclosed |
| EP-0139421-B1 | THIAZOLIDINE DERIVATIVES, THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | SANKYO COMPANY LIMITED (JP) | 1988-04-27 | — | — | EP | disclosed |
| EP-0207581-A2 | Thiazolidine derivatives, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1987-01-07 | — | — | EP | disclosed |
| US-4572912-A | Thiazolidine derivatives, their preparation and compositions containing them | SANKYO COMPANY LIMITED (JP) | 1986-02-25 | — | — | US | disclosed |
| JP-S6136284-A | THIAZOLIDINE DERIVATIVE AND PREPARATION THEREOF | SANKYO CO LTD | 1986-02-20 | — | — | JP | disclosed |
| EP-0139421-A1 | Thiazolidine derivatives, their preparation and compositions containing them | SANKYO COMPANY LIMITED (JP) | 1985-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184806-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | PPARG, PPARA, PPARD | MAPT 1770/4885MEN1 4688/4885KMT2A 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.